HER3/HER2 bispecific antibody that binds HER3 β-hairpin and HER2 domain II
A HVR-H2, bispecific technology, applied in the field of HER3/HER2 bispecific antibodies, bispecific antibodies, can solve problems such as inaccessibility
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment approach
[0467] 1. Use of at least one polypeptide comprising the amino acid sequence SEQ ID NO: 1 selected from the group consisting of a method for selecting an antibody binding to human HER3 for generating a bispecific HER3 / HER2 antibody:
[0468] SEQ ID NO: 13 TtSlyD-FKBP-Her3,
[0469] SEQ ID NO: 17 TtSlyDcas-Her3,
[0470] SEQ ID NO: 18 TtSlyDcys-Her3,
[0471] SEQ ID NO: 19 TgSlyDser-Her3, and
[0472] SEQ ID NO: 20 TgSlyDcys-Her3,
[0473] Wherein the HER3 antibody binds within the amino acid sequence PQPLVYNKLTFQLEPNPHT (SEQ ID NO: 1) of human HER3;
[0474] And such HER3 antibodies are then used to generate bispecific HER3 / HER2 antibodies.
[0475] 2. An isolated bispecific antibody that binds to human HER3 and binds to human HER2, wherein the antibody binds within the amino acid sequence PQPLVYNKLTFQLEPNPHT (SEQ ID NO: 1) comprised in a polypeptide selected from the group consisting of:
[0476] SEQ ID NO: 13 TtSlyD-FKBP-Her3,
[0477] SEQ ID NO: ...
Embodiment 1
[0548] Preparation of antigens and screening proteins - Generation of functional β-hairpin HER3 and β-hairpin HER4 constructs for selection of antibodies that bind HER3 β-hairpins and HER4 β-hairpins
[0549] To generate functional β-hairpin HER3 and HER4 constructs, the amino acid sequences of the β-hairpins of HER3 (SEQ ID NO: 1 ) and HER4 (SEQ ID NO: 2) were grafted into the SlyD polypeptide framework comprising the FKBP domain. In such constructs, the grafted β-hairpin is freely accessible, in contrast to the hidden structure in the native unactivated conformation of HER3 or HER4 (in the absence of a ligand such as HRG) (see figure 1 c and 1d, where the β-hairpin of HER3 is hidden).
[0550] All fusion SlyD polypeptides can be purified and refolded using almost the same protocol. Escherichia coli BL21(DE3) cells transformed with specific expression plasmids were grown at 37°C in LB medium containing corresponding antibiotics for selective growth (kanamycin 30 μg / ml...
Embodiment 2
[0560] a) Immunization and selection of HER3 antibody
[0561] To generate antibodies against HER3 and HER4 β-hairpins, Balb / C, NMRI or SJL mice were immunized with different antigens. The following proteins were used as antigens: full-length HER3 ECD, or epitope scaffold proteins TtSlyD-FKBP12-Her3, TtSlyDcys-Her3, TtSlyDcas-Her3, TgSlyDcys-Her3 and TgSlyDser-Her3. The TtSlyD-FKBP12-Her3 variant represents the first epitope scaffold for generating HER3 dimerization domain-specific antibodies. Although the general rationale for using SlyD variants as epitope scaffolds could have been demonstrated earlier using the first generation SlyD-FKBP12 scaffolds, improved scaffold variants with higher stability were developed. These SlyD variants were derived from Thermus thermophilus and Thermus gamma-resistant.
[0562] All mice were immunized three times at time points 0, 6 and 10 weeks after the start of the immunization campaign. At each time point each mouse was immunized...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com